bremelanotide sold brand name vyleesi medication used treat low sexual desire specifically used low sexual desire occurs menopause due medical problems psychiatric problems problems within given injection skin thigh common side effects include nausea pain site injection may also cause temporary increase blood pressure decrease heart rate dose darkening gums face medication peptide acts activating melanocortin bremelanotide approved medical use united states developed palatin us food drug administration fda considers firstinclass bremelanotide used treatment generalized hypoactive sexual desire disorder hsdd premenopausal specifically recommended condition without underlying cause medical psychiatric relationship used least minutes anticipated sexual one dose per hours eight doses per month stopped eight weeks improvement sexual desire associated due effects blood pressure generally transient increase systolic blood pressure mmhg diastolic blood pressure mmhg bremelanotide considered contraindicated people uncontrolled high blood pressure cardiovascular long bremelanotide used one day expected cause severe increases blood frequently encountered side effect bremelanotide nausea may intolerable use antinausea medications eg ondansetron prior administration bremelanotide may help reduce side effects may include flushing injection site reactions headache vomiting cough fatigue hot flushes paresthesia dizziness nasal congestion discoloration skin specifically hyperpigmentation may bremelanotide used eight times one discoloration may resolve upon stopping use bremelanotide may occur face gums experiments animals even high doses failed find negative consequence bremelanotide analysis clinical trials found obese women reduced calorie intake lost weight another drug similar mechanism action setmelanotide approved weight loss rare types bremelanotide meaningfully interact alcohol unlike flibanserin interaction alcohol major barrier however bremelanotide interact certain medications people take mouth slowing gastric motility bremelanotide thought reduce oral absorption bioavailability certain medications naltrexone bremelanotide nonselective agonist melanocortin receptors exception receptor acthtooltip adrenocorticotropic hormone acting primarily receptor bioavailability bremelanotide subcutaneous injection following subcutaneous injection bremelanotide maximal levels occur one hour range plasma protein binding bremelanotide bremelanotide metabolized via hydrolysis peptide elimination halflife bremelanotide hours range bremelanotide excreted urine bremelanotide cyclic heptapeptide lactam analogue αmelanocytestimulating hormone amino acid sequence also known substitutional name bremelanotide active metabolite melanotan ii lacks cterminal amide aside melanotan ii endogenous melanocytestimulating hormones like αmsh peptide analogues family bremelanotide include afamelanotide ndpαmsh modimelanotide setmelanotide studies early showed administration αmsh caused sexual arousal rats sparking interest αmsh scientists university arizona began developing αmsh analogs potential sunless tanning agents synthesized tested several analogs including peptides subsequently named melanotani melanotan early process one scientists mac conducting experiments peptide melanotan ii injected twice dose intended experienced eighthour erection along nausea pursue tanning agent melanotani licensed competitive technologies technology transfer company operating behalf university arizona australian startup called changed name clinuvel pursue sexual dysfunction agent melanotan ii licensed competitive technologies palatin palatin ceased development melanotanii synthesized patented began develop bremelanotide likely metabolite melanotanii differs melanotanii hydroxyl group melanotanii competitive technologies sued palatin breach contract try claim ownership parties settled palatin retaining rights bremelanotide returning rights melanotanii competitive technologies paying august palatin signed agreement king pharmaceuticals codevelop bremelanotide us jointly license outside us king paid palatin palatin conducted phase ii trials intranasal bremelanotide female sexual dysfunction fsd male erectile dysfunction ed trials halted fda due increased blood pressure clinical trial subjects palatin stopped development intranasal formulation four trials conducted ed last phase iib published king terminated codevelopment agreement shortly fda halted drug reformulated delivered injection trials continued fsd phase ii dosefinding trial fsd drug administered minutes sex showed promise highest dose transient signs high blood pressure two phase iii trials launched end palatin launched phase iii trials bremelanotide administered via palatin licensed european rights bremelanotide gedeon richter plc around million palatin received milestone payment around million started phase iii trials us september palatin gedeon richter terminated november palatin announced results phase iii trials shortly thereafter began seeking partner complete development january palatin amag pharmaceuticals agreed amag exclusively would complete development market bremelanotide north america two would work together license territories amag agreed pay million upfront million regulatory milestones million sales milestones tiered royalties ranging high single digit low double digit new drug application bremelanotide female sexual dysfunction accepted us food drug administration fda june prescription drug user fee act pdufa goal date set march approved use united states june httpsenwikipediaorgwikibremelanotide